Skip Navigation


JAC Advance Access originally published online on February 18, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/4/664    most recent
dkh129v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lofland, D.
Right arrow Articles by Johnson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lofland, D.
Right arrow Articles by Johnson, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 664-668
© 2004 The British Society for Antimicrobial Chemotherapy

In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698

Denene Lofland1,*, Stacey Difuntorum1, Andrew Waller2, John M. Clements2, Mellany K. Weaver3, James A. Karlowsky3 and Kirk Johnson1

1 Genesoft Pharmaceuticals, Inc., 7300 Shoreline Court, South San Francisco, CA, USA; 2 British Biotech Pharmaceuticals Ltd., Oxford, UK; 3 Focus Technologies, Herndon, VA, USA

Received 2 September 2003; returned 5 November 2003; revised 20 November 2003; accepted 23 December 2003

Objectives: BB-83698 is a peptide deformylase inhibitor currently in clinical trials in Europe. The purpose of this study was to provide additional susceptibility data from clinical isolates, including drug-resistant strains.

Methods: The in vitro activities of BB-83698 and comparators were determined against 281 streptococci, 154 Staphylococcus aureus, 110 Haemophilus influenzae and 50 Moraxella catarrhalis strains selected for their resistance phenotypes. Broth microdilution MICs and MBCs were determined according to NCCLS guidelines.

Results: The MIC90s were 0.25–0.5 mg/L for S. pneumoniae, including penicillin-, erythromycin-, levofloxacin- and multidrug-resistant strains. The MIC90s for Streptococcus pyogenes and Streptococcus agalactiae were 0.12 mg/L and for viridans streptococci, the MIC90 was 0.5 mg/L. Against S. aureus, including oxacillin- and levofloxacin-resistant strains, and vancomycin-intermediate strains, the MIC90 was 8 mg/L. Against ß-lactamase-negative and -positive H. influenzae, the MIC90s were 32 and 64 mg/L, respectively, and against both ß-lactamase-negative and -positive M. catarrhalis the MIC90 was 0.12 mg/L. In MBC studies, the ratio of MBC/MIC was 1:1 or 2:1 against 31% of S. pneumoniae, 33% of S. aureus, 63% of H. influenzae and 9% of M. catarrhalis.

Conclusions: Although BB-83698 has reduced in vitro activity against H. influenzae, it is a potent antimicrobial with excellent activity against streptococci and Moraxella.

Keywords: antimicrobials, antibiotics, bactericidal, MIC, MBC

* Corresponding author. Tel: +1-650-837-1872; Fax: +1-650-827-0475; E-mail: dlofland{at}genesoft.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Bacteriol.Home page
J. Huang, G. S. Van Aller, A. N. Taylor, J. J. Kerrigan, W.-S. Liu, J. M. Trulli, Z. Lai, D. Holmes, K. M. Aubart, J. R. Brown, et al.
Phylogenomic and Biochemical Characterization of Three Legionella pneumophila Polypeptide Deformylases.
J. Bacteriol., July 1, 2006; 188(14): 5249 - 5257.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. M. Bell, J. D. Turnidge, M. Inoue, S. Kohno, Y. Hirakata, Y. Ono, and R. N. Jones
Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan
J. Antimicrob. Chemother., February 1, 2005; 55(2): 276 - 278.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Ramanathan-Girish, J. McColm, J. M. Clements, P. Taupin, S. Barrowcliffe, J. Hevizi, S. Safrin, C. Moore, G. Patou, H. Moser, et al.
Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4835 - 4842.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.